Following successful national pilots of ctDNA blood tests for detection of non-small cell lung cancer and ESR1 in breast cancer, testing is now available as standard of care. Testing requires NHS Trusts to procure their own sample collection kits, which are then sent to certain regional Genomic Medicine Services (GMSs) for testing.
Those in the East Genomics region should order tests and send samples to the North Thames GMS. Find out more about ctDNA testing.
We have worked with Trusts across our region to support the funding and procurement of appropriate sampling kits. If you are unsure how to access testing, please contact:
- East of England Cancer Alliance - Liz Lawrence elizabeth.lawrence5@nhs.net
- East Midlands Cancer Alliance - Aisha Minhas aisha.minhas1@nhs.net
Benefits of ctDNA testing
Detection of ctDNA can be a fast and effective way to detect cancer and demand for these tests is expected to continue to grow.
Key benefits of testing include:
- Earlier access to targeted treatments and reduced need for repeated invasive procedures
- System-wide cost savings from diagnostic procedures for patients with failed genomic tests
- Cost savings from avoided mistreatment and associated consequences
- Improved quality of life for patients accessing treatment sooner
- Reduced cancer waiting times